Hyperthermia in Cancer Therapy

Dear Colleagues,

Moderate hyperthermia at 40–45 °C is a clinically proven radiosensitizer and chemosensitizer, and is used as a form of treatment at a number of tumor sites, including recurrent breast cancer, bladder cancer, cervical carcinoma, head and neck cancer, melanomas, peritoneal metastases, and soft tissue sarcomas. Adding hyperthermia to radiotherapy and chemotherapy improves the possibility for tumor control without increasing normal tissue toxicity. The effects of hyperthermia include re-oxygenation, the induction of the heat shock response, the inhibition of DNA-damage repair, and an enhanced immunological response. Ongoing research aims to comprehend more fully the effects of hyperthermia and further improve the clinical results.

This Topical Collection is pleased to invite submissions of manuscripts relating to multidisciplinary oncological research on therapeutic hyperthermia.  

This Topical Collection invites submissions of papers, articles, and reviews on the relevant topics and innovative and original research related to hypothermia, which include advanced drug-delivery systems for targeted tumor therapy using nanoparticles or thermo-sensitive liposomes, cancer immune therapy, magnetic nanoparticle (MNP) and magnetic fluid hyperthermia, photothermal treatments, a combination with PARP inhibitors or HSP-90 inhibitors, thermal dosimetry, and biological modeling.

The areas of research may include (but are not limited to) biological and preclinical research; the clinical application and results of local, loco-regional, whole-body hyperthermia, HIPEC, and HIVEC; the development of new heating technology; hyperthermia simulations; and treatment planning.

We look forward to receiving your contributions.

Dr. Hans Crezee
Prof. Dr. Holger Grüll
Prof. Dr. Elizabeth Repasky
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.